237 related articles for article (PubMed ID: 28411406)
1. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors.
Gu W; Dai Y; Qiang H; Shi W; Liao C; Zhao F; Huang W; Qian H
Bioorg Chem; 2017 Jun; 72():116-122. PubMed ID: 28411406
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of thieno[2,3-d]pyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors.
Li J; Gu W; Bi X; Li H; Liao C; Liu C; Huang W; Qian H
Bioorg Med Chem; 2017 Dec; 25(24):6674-6679. PubMed ID: 29146452
[TBL] [Abstract][Full Text] [Related]
4. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Tang Q; Wang L; Tu Y; Zhu W; Luo R; Tu Q; Wang P; Wu C; Gong P; Zheng P
Bioorg Med Chem Lett; 2016 Apr; 26(7):1680-4. PubMed ID: 26923692
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
9. Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.
Shi W; Qiang H; Huang D; Bi X; Huang W; Qian H
Eur J Med Chem; 2018 Oct; 158():814-831. PubMed ID: 30248654
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and molecular modeling study for some new 2-substituted benzimidazoles as dual inhibitors for VEGFR-2 and c-Met.
Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
Future Med Chem; 2018 Mar; 10(5):493-509. PubMed ID: 29431476
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
[No Abstract] [Full Text] [Related]
13. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
14. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
15. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
Zhang L; Zhao J; Zhang B; Lu T; Chen Y
Eur J Med Chem; 2018 Apr; 150():809-816. PubMed ID: 29602036
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2.
Qiang H; Gu W; Huang D; Shi W; Qiu Q; Dai Y; Huang W; Qian H
Bioorg Med Chem; 2016 Aug; 24(16):3353-8. PubMed ID: 27068889
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
[TBL] [Abstract][Full Text] [Related]
18. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
19. Discovery of thinopyrimidine-triazole conjugates as c-Met targeting and apoptosis inducing agents.
Wang L; Xu S; Liu X; Chen X; Xiong H; Hou S; Zou W; Tang Q; Zheng P; Zhu W
Bioorg Chem; 2018 Apr; 77():370-380. PubMed ID: 29421713
[TBL] [Abstract][Full Text] [Related]
20. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
